Form SC 13G/A BIOCRYST PHARMACEUTICALS Filed by: VANGUARD GROUP INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BioCryst Pharma (BCRX) PT Raised to $21 at Piper Sandler, 'we continue to recommend shares'
November 4, 2024 2:20 PM ESTPiper Sandler analyst Tyler Van Buren raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $21.00 (from $20.00) while maintaining a Overweight rating.
The analyst comments "Remain OW rated on BCRX shares after this mornings Q324 Orladeyo beat and narrowed FY24 Orladeyo revenue... More
BofA Securities on BioCryst Pharma (BCRX) 'Stock’s weakness offers particularly attractive entry point'
November 4, 2024 2:06 PM EST(Updated - November 4, 2024 2:16 PM EST)
BofA Securities analyst Tazeem Ahmad reiterated a Buy rating and $11.00 price target on BioCryst Pharma (NASDAQ: BCRX)
The analyst comments "BCRX reported $116.3mn in 3Q Orladeyo sales, slightly ahead of our $113.7mn and consensus $112.6mn. Mgmt highlights strong patient demand, noting US start forms were up 14.2% over the past 12 months and the paid drug rate improved to 74.8% (2Q: 74.4%). Additionally, 67 new US prescribers were added in 3Q, which is the highest add in the past eight quarters. The company narrowed FY24 Orladeyo sales guidance to... More
